金陵药业(000919) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥810,013,922.67, a decrease of 4.25% compared to ¥845,969,077.98 in the same period last year[5] - Net profit attributable to shareholders decreased by 49.07% to ¥22,981,989.14 from ¥45,124,738.44 year-on-year[5] - The basic earnings per share fell by 57.95% to ¥0.0370 from ¥0.0880 in the previous year[5] - Total operating revenue for the current period was ¥810,013,922.67, a decrease of 4.2% from ¥845,969,077.98 in the previous period[16] - Net profit for the current period was ¥25,174,905.26, down 50.8% from ¥51,100,581.72 in the previous period[17] - Total comprehensive income for the period was CNY 25,174,905.26, compared to CNY 51,100,581.72 in the previous period[18] - Net income attributable to the parent company was CNY 22,981,989.14, down from CNY 45,124,738.44 year-over-year[18] - Basic and diluted earnings per share were both CNY 0.0370, compared to CNY 0.0880 in the previous period[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,058,368,649.99, a decrease of 0.50% from ¥6,088,855,025.59 at the end of the previous year[5] - Total liabilities decreased to ¥1,184,699,361.12 from ¥1,240,278,401.94, a reduction of 4.5%[15] - The company's total equity attributable to shareholders increased by 0.60% to ¥3,814,019,370.53 from ¥3,791,090,837.42 at the end of the previous year[5] - The company's total equity increased to ¥4,873,669,288.87 from ¥4,848,576,623.65, an increase of 0.5%[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥57,763,324.07, an improvement of 29.91% compared to the outflow of ¥82,417,561.00 in the previous year[5] - Cash inflows from operating activities totaled CNY 748,869,645.07, slightly down from CNY 752,762,424.77[19] - Net cash outflow from operating activities was CNY -57,763,324.07, an improvement from CNY -82,417,561.00 in the previous period[19] - Cash inflows from investing activities were CNY 421,246,729.65, compared to CNY 313,928,236.83 in the previous period[20] - Net cash outflow from investing activities was CNY -418,189,065.94, worsening from CNY -60,856,143.85 year-over-year[20] - Cash and cash equivalents at the end of the period were CNY 1,104,500,475.08, down from CNY 1,937,777,334.28[20] - The company did not receive any cash from financing activities, compared to CNY 742,632,289.33 in the previous period[20] Expenses - The company's sales expenses surged by 223.21% to ¥22,006,480.98, attributed to increased marketing activities[8] - Total operating costs increased to ¥788,644,161.76, up from ¥782,749,272.77, reflecting a rise of 0.1%[16] - Research and development expenses were ¥21,182,611.02, slightly up from ¥20,776,182.16, indicating a focus on innovation[16] - The company experienced a 67.28% reduction in income tax expenses, amounting to ¥5,006,368.30 compared to ¥15,299,165.89 in the previous year[8] Investments - The company reported a significant increase in investment income, which rose by 151.44% to ¥9,392,399.03 from ¥3,735,392.36 year-on-year[8] - The company reported an investment income of ¥9,392,399.03, significantly higher than ¥3,735,392.36 in the previous period[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 35,998[10] - The largest shareholder, Nanjing New Industry Investment Group, holds 41.59% of shares, totaling 259,390,380 shares[10] - The company has not reported any changes in the top 10 shareholders due to securities lending[11] Future Plans and Legal Matters - The company plans to liquidate and deregister the Nanjing New Industry Medical Investment Fund Partnership[11] - The company has received a court ruling dismissing a retrial application related to a civil case[11] - The company is expected to disclose related party transactions for the year 2025[11] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[16] Other Information - Cash and cash equivalents decreased from ¥1,770,945,293.91 to ¥1,323,186,708.62, a decline of approximately 25.2%[13] - Trading financial assets increased from ¥706,046,500.54 to ¥1,042,055,857.89, an increase of approximately 47.6%[13] - Accounts receivable rose from ¥438,924,723.85 to ¥570,542,556.39, an increase of approximately 30%[13] - Inventory decreased from ¥271,624,277.17 to ¥250,837,970.04, a decline of approximately 7.6%[13] - The company’s first quarter report was not audited[21]